Drug Trial Radar · NCT03540758
Regulation of Endogenous Glucose Production by Central KATP Channels
Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Aug 1, 2018
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Albert Einstein College of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institutes of Health (NIH); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); American Diabetes Association; Rutgers University; Vanderbilt University Medical Center
- First posted
- May 30, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (participant)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Type 2 diabetes (T2D) affects the ability of the body to process glucose (sugar). Under fasting conditions, the liver is able to make sugar to maintain glucose levels in an important process called endogenous glucose production (EGP). Previous studies suggest that the central nervous system (CNS), including the brain, helps to regulate levels of glucose in the body by communicating with the liver. This process can be impaired in people with type 2 diabetes, and can contribute to the high level of glucose seen in these individuals. The purpose of this study is to understand how activating control centers of the brain with a medication called diazoxide can affect how much glucose (sugar) is made by the liver. This is particularly important for people with diabetes who have very high production of glucose, which in turn can lead to diabetes complications.
Conditions
- Diabetes Mellitus
- Glucose Metabolism Disorders
Interventions
DiazoxideDrug
Non-diabetic participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) during the pancreatic clamp study.
Nicotinic acidDrug
Non-diabetic participants will receive nicotinic acid infusion based on weight (0.01 mg/kg/min) during the pancreatic clamp study.
PlaceboDrug
Non-diabetic participants will receive placebo and undergo the pancreatic clamp study. T2D participants will have their blood sugar levels normalized, and will then receive a taste-matched placebo for diazoxide before undergoing the pancreatic clamp study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Endogenous glucose production (EGP) rateTime frame: 7 hour infusions, 4 days in total, separated at least 1 month apart, up to 1 year duration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Albert Einstein College of Medicine
The Bronx, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.